Zealand Pharma A/s

Jesper Mosolff Mathiesen

Dieter Wolfgang Hamprecht

Lise Giehm

Henrik Kofoed Munch

Jesper Skodborg Villadsen

Alexander Heim-Riether

Giacomo Fossati

Rasmus Just

Maria Alexandrovna Deryabina

Oliver Demmer

Jesper Sloth Villadsen

Jolanta Skarbaliene

The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.

Amylin analogues

The present invention relates to amylin analogs and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogs have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.

Growing community of inventors

Farum, Denmark

Jesper Mosolff Mathiesen